13485cert

Archive for the ‘Scrutiny Process’ Category

MedTech Forum 2012: “S is for scrutiny, which we’re not sure about”

In CE Mark, CE Medical, Medical CE, PMA, Scrutiny Process on October 16, 2012 at 12:50 pm

Erik has the distinct honor of being my first “Reblog”. In this blog posting he has done an exceptional job of capturing the political issues behind the proposed EU Medical Device Regulation. Erik is as close to the source as someone outside the Commission can be, and his knowledge is evident throughout his frequent postings–which I read and re-read each week.

His firm is offering a free on-line seminar related to the new regulations on November 14th. Make sure that you register with Marjon ahead of time.

Click on this link for information about the seminar.

medicaldeviceslegal

“S is for scrutiny, which we’re not sure about”, that would be more or less the take home message of the MedTech Forum in Brussels that I attended last week from Wednesday to Friday. This conference is an ideal moment to take stock of the EU medtech industry. No wonder that everyone was there to discuss the newly proposed medical devices and in vitro diagnostics regulations. If you want a summary report of the plenary sessions, a good picture emerges from the tweets on the hashtag #mtf2012 by @meddevlegal (that’s me), @clinicamedtech, @emdt_editor and @maxwellmedtech between 10 and 12 October 2012. The picture that emerges is that the industry welcomes the new rules in general, thinks some details must be clarified and is worried about what the proposed scrutiny procedure will look like after it has gone through the legislative procedure and the Parliament has had its way with the…

View original post 1,601 more words

Who’s Afraid of the Proposed European Scrutiny Process?

In CE Mark, CE Medical, Class IIb, Class III, Medical CE, PMA, Scrutiny Process on October 12, 2012 at 2:22 am

For those of you that are not familiar with the “Scrutiny Process”, I am referring specifically to Article 44 of the proposed EU regulations for medical devices. This process is first alluded to at the end of section 3.5 in the “Explanatory Memorandum” (i.e. – the 13 pages preceding the proposal for the regulation of medical devices).

I was looking for a video that matched up with my title and when I saw this TECHNO music video.

The US already has a pre-market approval process that we fondly refer to as the PMA process. In response to the PIP scandal, the European Parliament’s ENVI Committee (Committee on the Environment, Public Health and Food Safety) proposed a pre-market approval process as part of a press release issued on April 25, 2012. In response to this political pressure, the Commission has proposed a “Scrutiny Process” that involves preparation of a Notified Body “Summary Evaluation Report” and verification that the conformity assessment was adequate by the Coordinating Competent Authority. A similar process is outlined in MEDEV 2.11/1 rev. 2, a guidance document regarding animal tissues, and the Commission Regulation (EU) No 722/2012 of 8 August 2012. The proposed scrutiny process allows competent authorities to take a “second look” and review the findings of the Notified Body that would be issuing a CE Certificate for these high risk devices. The review process is supposed to be concluded within 60 days, but the review time limit is suspended if the Competent Authorities request additional information or product samples within the first 30 days.

In section 3.5 of the Explanatory Memorandum, the Commission states that this scrutiny process “should be the exception rather than the rule and should follow clear and transparent criteria.” The criteria for invoking the scrutiny process are defined in five points 5a) through 5e) of Article 44. The five points leave room for interpretation by Competent Authorities, and the medical device industry is concerned that the review process for Class IIb and Class III devices will be delayed by at least 60 days on a regular basis. The process could easily be delayed by as much as six months when there are requests for additional information and samples.

The “Legislative Financial Statement” (i.e. – the 19 pages immediately following the proposal for the regulation of medical devices) defines a monitoring process for the scrutiny process in the “Indicator of results and impact” (Section 1.4.4). The risk of delaying access to market for innovative devices is also identified in the “Risk(s) identified” (Section 2.2.1). Therefore, the need for a control mechanism is identified in “Control method(s) envisaged” (Section 2.2.2). This will be the responsibility of the Commission to draft a guidance document to define the control method(s). Until industry has an opportunity to review such a guidance document, executives will continue to voice their concerns and apply their own political pressure to the European Parliament.

%d bloggers like this: